STLN logo

STARLING ONCOLOGY INC

STLNNASDAQ
๐Ÿ† #3146 by market capEarnings Mar 10 ยท PostUS Equity
โ€”โ€”
Quote unavailable
๐Ÿ””
Track STLN
Get earnings, price moves & breaking news on Telegram
Track
24hโ€”
7dโ€”
14dโ€”
30dโ€”
ytdโ€”
1yโ€”
๐ŸฆMarket Cap
$306M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
38.4%
High Growth
๐Ÿ“ŠGross Margin
15.7%
Thin
๐Ÿ’ตFCF Margin
2.2%
Thin
โš–๏ธP/S Ratio
0.5x
Cheap
Otter Score
โ€”
Insufficient data
No chart data available for STLN.

Trading Snapshot

Day Range
โ€”
52-Week Range
$3.13 โ€“ $7.13
Volume (shares)
โ€”
Avg Volume (shares)
โ€”
Shares Outstanding
101.9M
Next Earnings
2027-03-10

Fundamentals Snapshot

Annual Revenue
$503M
Last Q Revenue
$170M
P/E Ratio
โ€”
P/S Ratio
0.5x
EPS (TTM)
$-0.36
Dividend Yield
โ€”
STLN logo

STARLING ONCOLOGY INC

STLN
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About STARLING ONCOLOGY INC

Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.